Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells

Eva Vacas, Laura Muñoz-Moreno, Pedro L. Valenzuela, Juan C. Prieto, Andrew V Schally, María J. Carmena, Ana M. Bajo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells. We evaluated by Western blot assays the effect of GHRH on transactivation of EGF receptor (EGFR) as well as the elements implicated. We assessed the effect of GHRH on migration capability of MDA-MB-468 cells as well as the involvement of EGFR in this process by means of wound-healing assays. Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. The cross-talk between EGFR and GHRHR may be impeded by combining drugs acting upon GHRH receptors and EGFR family members. This combination of GHRH receptors antagonists with inhibitors of EGFR signalling could enhance the efficacy of both types of agents as well as reduce their doses increasing therapeutic benefits in management of human breast cancer.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalPeptides
Volume86
DOIs
StatePublished - Dec 1 2016

Fingerprint

Triple Negative Breast Neoplasms
Growth Hormone-Releasing Hormone
Epidermal Growth Factor Receptor
Transcriptional Activation
Cells
Breast Neoplasms
Epidermal Growth Factor
Assays
Chemical activation
Ligands
Hormone Antagonists
Phosphorylation
Chemotherapy
Metalloproteases
Progesterone Receptors
Estrogen Receptors
Wound Healing
Tyrosine
Intercellular Signaling Peptides and Proteins
Western Blotting

Keywords

  • Cell migration
  • EGFR
  • GHRH
  • GHRH antagonist
  • Transactivation
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Physiology
  • Biochemistry
  • Endocrinology
  • Cellular and Molecular Neuroscience

Cite this

Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells. / Vacas, Eva; Muñoz-Moreno, Laura; Valenzuela, Pedro L.; Prieto, Juan C.; Schally, Andrew V; Carmena, María J.; Bajo, Ana M.

In: Peptides, Vol. 86, 01.12.2016, p. 153-161.

Research output: Contribution to journalArticle

Vacas, Eva ; Muñoz-Moreno, Laura ; Valenzuela, Pedro L. ; Prieto, Juan C. ; Schally, Andrew V ; Carmena, María J. ; Bajo, Ana M. / Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells. In: Peptides. 2016 ; Vol. 86. pp. 153-161.
@article{c9bfc54f5a1441e68dafdb499de801b7,
title = "Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells",
abstract = "Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells. We evaluated by Western blot assays the effect of GHRH on transactivation of EGF receptor (EGFR) as well as the elements implicated. We assessed the effect of GHRH on migration capability of MDA-MB-468 cells as well as the involvement of EGFR in this process by means of wound-healing assays. Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. The cross-talk between EGFR and GHRHR may be impeded by combining drugs acting upon GHRH receptors and EGFR family members. This combination of GHRH receptors antagonists with inhibitors of EGFR signalling could enhance the efficacy of both types of agents as well as reduce their doses increasing therapeutic benefits in management of human breast cancer.",
keywords = "Cell migration, EGFR, GHRH, GHRH antagonist, Transactivation, Triple-negative breast cancer",
author = "Eva Vacas and Laura Mu{\~n}oz-Moreno and Valenzuela, {Pedro L.} and Prieto, {Juan C.} and Schally, {Andrew V} and Carmena, {Mar{\'i}a J.} and Bajo, {Ana M.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.peptides.2016.11.004",
language = "English (US)",
volume = "86",
pages = "153--161",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells

AU - Vacas, Eva

AU - Muñoz-Moreno, Laura

AU - Valenzuela, Pedro L.

AU - Prieto, Juan C.

AU - Schally, Andrew V

AU - Carmena, María J.

AU - Bajo, Ana M.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells. We evaluated by Western blot assays the effect of GHRH on transactivation of EGF receptor (EGFR) as well as the elements implicated. We assessed the effect of GHRH on migration capability of MDA-MB-468 cells as well as the involvement of EGFR in this process by means of wound-healing assays. Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. The cross-talk between EGFR and GHRHR may be impeded by combining drugs acting upon GHRH receptors and EGFR family members. This combination of GHRH receptors antagonists with inhibitors of EGFR signalling could enhance the efficacy of both types of agents as well as reduce their doses increasing therapeutic benefits in management of human breast cancer.

AB - Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells. We evaluated by Western blot assays the effect of GHRH on transactivation of EGF receptor (EGFR) as well as the elements implicated. We assessed the effect of GHRH on migration capability of MDA-MB-468 cells as well as the involvement of EGFR in this process by means of wound-healing assays. Our findings demonstrate that in MDA-MB-468 cells the stimulatory activity of GHRH on tyrosine phosphorylation of EGFR is exerted by two different molecular mechanisms: i) through GHRH receptors, GHRH stimulates a ligand-independent activation of EGFR involving at least cAMP/PKA and Src family signaling pathways; ii) GHRH also stimulates a ligand-dependent activation of EGFR implicating an extracellular pathway with an important role for metalloproteinases. The cross-talk between EGFR and GHRHR may be impeded by combining drugs acting upon GHRH receptors and EGFR family members. This combination of GHRH receptors antagonists with inhibitors of EGFR signalling could enhance the efficacy of both types of agents as well as reduce their doses increasing therapeutic benefits in management of human breast cancer.

KW - Cell migration

KW - EGFR

KW - GHRH

KW - GHRH antagonist

KW - Transactivation

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84995616529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995616529&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2016.11.004

DO - 10.1016/j.peptides.2016.11.004

M3 - Article

C2 - 27816751

AN - SCOPUS:84995616529

VL - 86

SP - 153

EP - 161

JO - Peptides

JF - Peptides

SN - 0196-9781

ER -